September 5, 2012Expert Opinion on Drug Safety
Safety profile and bleeding risk of ticagrelor compared with clopidogrel
Key result
Ticagrelor provides an overall mortality benefit and more rapid, consistent platelet inhibition compared to clopidogrel in patients with acute coronary syndromes.
Why the study?
Does ticagrelor have a better efficacy and safety profile compared to clopidogrel in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes (ACS)
Comparison
Ticagrelor vs Clopidogrel
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support ticagrelor preference in ACS; leaves open confirmation in contemporary practice.
Structured PICO
Does ticagrelor have a better efficacy and safety profile compared to clopidogrel in patients with acute coronary syndromes?
P
Population
Patients with acute coronary syndromes (ACS)
I
Intervention
Ticagrelor
C
Comparator
Clopidogrel
O
Outcome
Efficacy and safety end points (including mortality, bleeding, dyspnea, and ventricular pauses)safety
Ticagrelor is preferred over clopidogrel in ACS due to its mortality benefit and superior platelet inhibition, despite mild and self-limiting dyspnea.
Cite This Study
May et al. (2012) conducted a review in Acute coronary syndromes (ACS). Ticagrelor vs. Clopidogrel was evaluated. Ticagrelor provides an overall mortality benefit and more rapid, consistent platelet inhibition compared to clopidogrel in patients with acute coronary syndromes.